News & Updates
Excerpt from the Press Release: When COVID-19 shut down the world’s economies, governments across the globe, including the United States, began to pour money into vaccine research and development. Those funds led to the rapid development and deployment of vaccines, but few therapeutics against the virus have achieved the same speed of development. And that may…
Read More
On May 25th, 2021 TrialStat’s very own Christopher Kata, and Heather Williams hosted an incredible webinar with our guest Speaker John Amrhein, VP of McDougall Scientific. John presented his perspective on “Accelerating Trials Through Innovative Clinical Trial Designs” and taking questions from our live audience! Download the Slide Deck, and Watch The Webinar Recording On…
Read More
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Freenome, the privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection using a routine blood draw, today announced results from two different studies using “CRC – Microsimulation of Adenoma Progression and Screening”, or CRC-MAPS™, a novel semi-Markov microsimulation model of…
Read More Meet with Christopher Kata, Director of Sales & Marketing on June 27 – July 1st! Christopher Kata, Director of Sales & Marketing905 [email protected] When: June 27th – July 1st 2021Where: It’s Virtual!Registration: https://www.diaglobal.org/en/cart Recognizing and adapting to a new era of global change and uncertainty, DIA’s key tenets remain unchanged. Patients are our story, we…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass. & FARGO, N.D.–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Aldevron, LLC, the leading provider of high-quality plasmid DNA, mRNA and recombinant proteins necessary for vaccines, gene and cell therapy, gene editing and diagnostic applications, have announced their expanded collaboration in…
Read More
Excerpt from the Press Release: BOSTON–(BUSINESS WIRE)–Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for the combination of its investigational RAF/MEK inhibitor VS-6766, with defactinib, its FAK inhibitor, for…
Read More
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 23, 2021 (GLOBE NEWSWIRE) — InspirMed Inc., a subsidiary of TLC (Nasdaq: TLC, TWO: 4152) that specializes in the development of proprietary inhalable liposome formulation programs, recently presented data on the potential advantages of inhalable liposome formulations of antiviral drugs at the 23rd International Society…
Read More
Excerpt from the Press Release: NEWTOWN, Pa., May 21, 2021 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the first patient has been dosed in the U.S. Phase 1 clinical trial of ON 123300, the Company’s proprietary, novel…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass. and WESTMINSTER, Colo., May 12, 2021 /PRNewswire/ — Leap Therapeutics (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, andFlagship Biosciences, the leader in data-centric pathology and tissue analysis, today announced that they have developed an image analysis RNAscope® assay that is being used successfully for prospective patient enrollment in a clinical trial.…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced the completion of enrollment in its Phase 2a trial advancing GEM103 as a potential add-on therapy for patients suffering from wet AMD and requiring continued anti-vascular…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?